Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Completed
Ipsen
Phase 4
2014-05-01
Circulating tumour cells (CTCs) are detectable in the blood in around 50% of patients with
functioning NeuroEndocrine Tumours (NET) arising in the midgut area (tumours which are
secreting hormones and are located in the area in the middle of the digestive system) and
their presence usually means that the prognosis for the patient is poor. CTCs have also been
shown to be valuable as predictive markers following treatment and there is increasing
interest in using CTCs as 'liquid biopsies' that can help to inform treatment decisions. CTC
analysis has the benefit of being relatively non- invasive and quick compared with a
conventional CT scan and is therefore an attractive method of monitoring the tumour
throughout the treatment period.
The purpose of this study is to assess the clinical value that enumeration will have in
predicting the clinical symptomatic response and progression free survival in patients
receiving Somatuline Autogel for functioning midgut NETs over a one year period.
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
Completed
Ipsen
Phase 1/Phase 2
2015-03-01
The objectives of the protocol is to determine the maximum tolerated dose and to investigate
the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly.
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
Completed
Ipsen
Phase 3
2014-10-01
The purpose is to compare the efficacy and safety of lanreotide autogel® 60mg, 90mg or 120mg
with lanreotide 40mg PR in subjects with active acromegaly.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
